Compare FOA & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOA | HBIO |
|---|---|---|
| Founded | 2013 | 1901 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.6M | 26.5M |
| IPO Year | 2021 | 2000 |
| Metric | FOA | HBIO |
|---|---|---|
| Price | $14.49 | $7.96 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $26.00 | $18.00 |
| AVG Volume (30 Days) | ★ 57.2K | 16.5K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 216.95 | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $497,432,000.00 | $116,176,000.00 |
| Revenue This Year | $0.58 | $4.77 |
| Revenue Next Year | $6.91 | $8.55 |
| P/E Ratio | $35.10 | ★ N/A |
| Revenue Growth | ★ 47.09 | N/A |
| 52 Week Low | $13.73 | $0.38 |
| 52 Week High | $29.79 | $8.40 |
| Indicator | FOA | HBIO |
|---|---|---|
| Relative Strength Index (RSI) | 28.72 | 59.23 |
| Support Level | N/A | $5.84 |
| Resistance Level | $20.17 | $8.19 |
| Average True Range (ATR) | 0.63 | 0.19 |
| MACD | 0.12 | -0.07 |
| Stochastic Oscillator | 22.96 | 35.29 |
Finance of America Companies Inc provides home equity-based financing solutions for modern retirement and offers capital markets and portfolio management capabilities to optimize loan distribution to investors. The Company operates through two segments: Retirement Solutions and Portfolio Management. The Retirement Solutions segment handles loan origination, including HECM and non-agency reverse mortgage loans, generating revenue from origination fees and initial gains, with loans transferred to the Portfolio Management segment. The Portfolio Management segment, which generates the majority of revenue, provides securitization, loan sales, risk management, and asset management services, and earns revenue from net interest income, fair value changes, and servicing-related income.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.